TG Therapeutics
Update in progressTGTX (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell–mediated diseases in the U.S. and abroad. It markets BRIUMVI, an anti-CD20 antibody for adults with relapsing forms of multiple sclerosis. Its pipeline includes Ublituximab IV (glycoengineered anti-CD20), TG-1701 (oral BTK inhibitor), and TG-1801 (CD47/CD19 bispecific). Licenses: LFB, GTC, Ildong, Jiangsu Hengrui. Founded 1993, based in Morrisville, NC.
Company score
- Sentiment
- 0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!